Jefferies & Company Inc. Has Just Reported a Downgrade of Carl Zeiss Meditec (ETR:AFX) with a EUR 21.40 Targeted Price


Carl Zeiss Meditec (ETR:AFX) Receives a Downgrade

In analysts note shared with investors and clients on 17 December, research analysts at Jefferies & Company Inc.’s equity division downgraded the rating for shares of Carl Zeiss Meditec (ETR:AFX) to a “Underperform”. They now have a key price target of EUR 21.40 on AFX shares, equating to -21.78% more downside.

From a total of 7 analysts covering Carl Zeiss Meditec (ETR:AFX) stock, 4 rate it a ”Buy”, 1 a “Sell”, and 2 a ”Hold”. This means that 57% of the ratings are positive. The highest target price is €29 while the lowest target price is €19.80. The mean of all analyst targets is €26.02 with a -4.72% below today’s (€27.31) stock price. Carl Zeiss Meditec was the topic of 9 analyst reports since August 7, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on October 23 with “Neutral” rating. Independent Research maintained shares with “Hold” rating and €26 target share price in a report from an August 12. DZ-Bank AG upgraded AFX stock in a recent report from October 3 to “Buy” rating. Kepler Cheuvreux upgraded the rating on August 7. Kepler Cheuvreux has a “Buy” rating and a €28 price target on shares. Finally, Berenberg upgraded the stock to “Buy” rating in a report issued on a September 15.

The stock increased 6.99% or EUR 1.78 on December 16, striking EUR 27.31. Approximately 86,525 shares of stock traded hands or 117.83% up from the average. Carl Zeiss Meditec AG (ETR:AFX) has declined 6.80% since May 20, 2015 and is downtrending. It has underperformed by 4.18% the S&P500.

 Jefferies & Company Inc. Has Just Reported a Downgrade of Carl Zeiss Meditec (ETR:AFX) with a EUR 21.40 Targeted Price

Carl Zeiss Meditec AG is a Germany-based medical technology solutions supplier. The company has a market cap of 2.15 billion EUR. The Firm operates, along with its subsidiaries, in two business areas: Ophthalmology and Microsurgery. It has 32.04 P/E ratio. The Ophthalmology business area is subdivided into two business units: the Ophthalmology systems unit covers a range of laser and diagnostic systems for ophthalmology, and the Surgical Ophthalmology unit combines the Company’s activities in the field of ophthalmic implants and disposables.